Pharmacoeconomic Analysis of Chronic Heart Failure Drug Therapy in Patients With Comorbid Conditions

Zyryanov, S. K.; Cheberdа, А. E.; Коломиец, В. М.

doi:10.20996/1819-6446-2018-14-2-167-175

Cited by 3 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 22 full-text publications, 15 conference abstracts, and 5 HTA reports (1 each from the NICE [17], US ICER [61], CADTH [58], PBAC [60] and SMC [59]) were included. Of these, seven were from the US [18,20,30,33,35,52,61], three from Canada [51,55,58], three from Australia [27,56,60], and two each from the UK [17,41], Germany [32,48], Italy [29,50], the Netherlands [21,43], Russia [53,57], and Singapore [19,40] From additional bibliography (n = 1) chronic HFrEF in the outpatient setting, three studies modeled patients stabilized in hospital after an acute decompensation for HF [33,56,57] (Supplementary Table S4).…”

Section: Summary Of Studiesmentioning

confidence: 99%

Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review

et al. 2022

View full text Add to dashboard Cite

Objectives To summarize cost-effectiveness (CE) evidence of sacubitril/valsartan for the treatment of heart failure (HF) patients with reduced ejection fraction (HFrEF). The impact of different modeling approaches and parameters on the CE results is also described. Methods We conducted a systematic literature review using multiple databases: Embase®; MEDLINE®; MEDLINE®-In Process; NIHR CRD database including DARE, NHS EED, and HTA databases; and the Cost Effectiveness Analysis registry. We also reviewed HTA countries’ websites to identify CE reports of sacubitril/valsartan, published up to 25-July-2021. Articles published in English as full-texts, conference-abstracts, or HTA reports were included. Results We included 44 CE models [39 from 37 publications (22 full-texts; 15 conference-abstracts) and 5 HTAs; Europe, n = 20; North and South Americas, n = 14; Asia and Australia, n = 10]. Most models adopted a Markov structure with constant transition probabilities of events (n = 27) or a mix of Markov and regression-based models (n = 16), with variations in structural assumptions and chosen parameters. Study authors concluded sacubitril/valsartan to be a cost-effective therapy in 37/41 models in chronic HFrEF patients and 2/3 models in hospitalized patients stabilized after an acute decompensation for HF. CE models showing sacubitril/valsartan not to be a cost-effective treatment generally modeled a shorter time horizon. Effect of sacubitril/valsartan on cardiovascular and all-cause mortality, cost, duration of effect and time horizon was the main model drivers. Conclusions Most evidence indicated sacubitril/valsartan is cost-effective in HFrEF. The use of a lifetime horizon is recommended in future models as HF is a chronic disease. Data on the CE of sacubitril/valsartan in the inpatient setting were limited and further research is warranted.

show abstract

Section: Summary Of Studiesmentioning

confidence: 99%

Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Для проведения клинико-экономического анализа была построена фармакоэкономическая модель, в которой в анализируемую популяцию включались пациенты в возрасте 18 лет и старше, с диагностированной ХСН с систолической дисфункцией, выписанные после госпитализации по поводу ОДСН. В отличие от ранее проведенного нами исследования [12], в котором клинико-экономический анализ проводился для амбулаторной популяции пациентов с наличием коморбидной патологии, в данной работе в анализ включались пациенты, получающие сравниваемые альтернативные варианты лечения в течение 1 года после госпитализации по поводу ОДСН. Пациенты включались вне зависимости от наличия у них сопутствующих заболеваний.…”

Section: клиника и фармакотерапияunclassified

“…В Российской Федерации (РФ) распространённость хронической сердечной недостаточности (ХСН) I-IV функционального класса (ФК) по NYHA в популяции составляет до 8,5% (12,35 млн человек), тяжелая ХСН (III-IV ФК) встречается у 3,1% населения (4,5 млн человек) [2]. Смертность при ХСН составляет 6% в год и превышает общепопуляционную в 10 раз [2].…”

unclassified

Comparative pharmacoeconomic analysis of medication for patients after acute decompensated heart failure

Зырянов

Ушкалова

2020

Russ J Cardiol

Self Cite

View full text Add to dashboard Cite

Aim. Pharmacoeconomic comparison of medication management strategies (valsartan+ sacubitril) for patients with heart failure (HF), stabilized after an episode of acute decompensated heart failure (ADHF).Material and methods. “Cost — effectiveness analysis” and “Budget impact analysis” were used. The study is conducted in terms of the interests of Russian Federation health care system and budgets of individual regions.Results. The use of valsartan+sacubitril combination will require an increase in direct medical costs for 1 year by 38,5% compared with enalapril. The cost of one life year gained when using the valsartan+sacubitril combination was 307,294 rubles. When estimating data for the target ADHF population (n=200,769), valsartan+sacubitril will require additional 4,4 billion rubles per year. At the same time, this will save almost 17 thousand lives and prevent 126 thousand ambulance calls and 33,9 thousand rehospitalizations, including more than 6,5 thousand in the intensive care unit.Conclusion. The use of valsartan+sacubitril combination in HF patients hospitalized with ADHF is cost-effective management strategy that significantly improves the prognosis in this category of patients.

show abstract

Modern genetic markers of chronic heart failure

Zimina,

Gorbunova,

Tolmacheva

et al. 2023

jour

View full text Add to dashboard Cite

Due to the rapid spread and large coverage, chronic heart failure (CHF) is reaching the state of a pandemic of the 21st century. Among elderly patients, HF is the main reason for referral to hospital. Half of patients with this pathology die within 5 years after diagnosis. Currently, the diagnosis of CHF is gaining momentum due to the importance of this disease. There are more and more studies and works that prove the high sensitivity of cardiac markers for diagnosing CHF. There are many genes that can participate in the formation of a hereditary predisposition, both independently and through interaction with each other. This literature review was carried out in order to identify genetic markers for diagnosing CHF. The results of studies that can be used to analyze the effect of polymorphism of the genes coding angiotensinogen, angiotensin-converting enzyme, β2-adrenoreceptor, nitric oxide synthase, aldosterone synthase are presented. An in-depth study of molecular genetic markers, as well as determining their significance in the development of heart failure, is an urgent problem of modern medicine, the solution of which will make it possible to carry out effective prevention of cardiovascular complications, optimize treatment and improve the prognosis of patients. Information on the topic from publications based on the PubMed, eLibrary databases was used.

show abstract

Pharmacoeconomic Analysis of Chronic Heart Failure Drug Therapy in Patients With Comorbid Conditions

Cited by 3 publications

References 17 publications

Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review

Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review

Comparative pharmacoeconomic analysis of medication for patients after acute decompensated heart failure

Modern genetic markers of chronic heart failure

Contact Info

Product

Resources

About